Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension

Table 4 Impact of PAH-specific therapy and anticoagulation on health-related quality of life scores in SSc-PAH determined through mixed effects linear regression modeling

Variables	Coefficient (95% CI)	P value
Determinants of SF-36 physical component score
Female gender	0.4 (−3.9, 4.7)	0.85
Age at PAH diagnosis, years	0.1 (−0.1, 0.2)	0.29
Diffuse disease subtype	−0.3 (−3.8, 3.2)	0.87
Combination therapy	1.7 (−1.5, 5.0)	0.29
Anticoagulation therapy	−3.7 (−7.1, −0.3)	0.03
GIT involvement^a	4.7 (0.9, 8.6)	0.01
Digital ulcers^a	−3.7 (−7.2, −0.1)	0.04
Determinants of SF-36 mental component score
Female gender	−3.5 (−8.6, 1.6)	0.18
Age at PAH diagnosis, years	−0.1 (−0.2, 0.1)	0.67
Diffuse disease subtype	−1.1 (−5.2, 3.0)	0.59
Combination therapy	5.2 (1.3, 9.1)	0.01
Anticoagulation therapy	−2.5 (−6.6, 1.6)	0.22
GIT involvement^a	−1.6 (−6.2, 2.9)	0.48
Digital ulcers^a	2.8 (−1.5, 7.1)	0.19
Determinants of SHAQ score
Female gender	0.3 (−0.5, 0.9)	0.46
Age at PAH diagnosis, years	−0.1 (−0.1, −0.1)	0.02
Diffuse disease subtype	−0.5 (−1.1, 0.2)	0.13
Combination therapy	−0.3 (−0.8, 0.3)	0.38
Anticoagulation therapy	0.3 (−0.3, 0.9)	0.28
GIT involvement^a	0.7 (0.1, 1.3)	0.03
Digital ulcers^a	−0.1 (−0.7, 0.5)	0.79

Abbreviations: SSc systemic sclerosis, PAH pulmonary arterial hypertension, GIT gastrointestinal involvement, SHAQ scleroderma health assessment questionnaire
^aDisease manifestations present if present at PAH diagnosis or at any follow-up visit following PAH diagnosis

ISSN: 1478-6362